Theratechnologies Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.0M
Doctors Paid
4,353
Transactions
23,746
2024 Total
$486,804
Payment Breakdown by Category
Research$3.3M (41.1%)
Consulting$1.6M (20.2%)
Food & Beverage$561,770 (7.0%)
Travel$338,906 (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.3M | 500 | 41.1% |
| Consulting Fee | $1.6M | 565 | 20.2% |
| Honoraria | $1.1M | 586 | 14.0% |
| Grant | $662,312 | 22 | 8.3% |
| Food and Beverage | $561,770 | 20,460 | 7.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $381,929 | 352 | 4.8% |
| Travel and Lodging | $338,906 | 757 | 4.2% |
| Education | $28,877 | 504 | 0.4% |
Payments by Type
General
$4.7M
23,246 transactions
Research
$3.3M
500 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) | $469,339 | 2 | 124 |
| Visceral Adiposity Measurement and Observation Study | $457,930 | 0 | 44 |
| A Phase 3 Study of the Safety of Trogarzo Administered as an Undiluted IV Push over a Reduced Interval or as an Intramuscular Injection in Clinically Stable HIV-1 Infected Trogarzo Experienced Patients and Healthy HIV-uninfected Volunteers | $439,459 | 1 | 49 |
| EMR 200147-501 EGRIFTA-Tesamorelin | $362,984 | 4 | 131 |
| Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease | $325,000 | 0 | 1 |
| Tesamorelin Effects on Liver Fat and Histology in HIV A Collaborative UO1 Grant | $294,283 | 0 | 19 |
| EMR 200147-500 EGRIFTA | $239,578 | 3 | 80 |
| Tesamorelin effects in adult living with fatty liver | $206,428 | 0 | 10 |
| Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons | $130,134 | 0 | 18 |
| Lipidomic Assessment of Tesamorelin Effects in HIV NAFLD | $99,938 | 0 | 1 |
| Role of Growth Hormone in the Pathogenesis and Treatment of Cardiac Steatosis and Diastolic Dysfunction in HIV | $80,001 | 0 | 3 |
| Proteomic Assessment of Tesamorelin Effects in HIV NAFLD | $73,001 | 0 | 1 |
| Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected persons | $45,616 | 0 | 3 |
| Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes following Peripheral Nerve Injury | $32,772 | 0 | 4 |
| The Effects of Growth Hormone Releasing Hormone on Cognitive Function in Individuals with Mild Cognitive Impairment | $16,813 | 0 | 8 |
| 10070130 | $6,622 | 0 | 1 |
| The Effect of Growth Hormone Relasing Hormoone on Cognitive Function in Individuals with Mild Cognitive Impairment | $3,348 | 0 | 1 |
| Trogarzo TM ibalizumab-uiyk for multidrug resistant HIV-2 | $1,135 | 1 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Claudia Martorell, Md, MD | Infectious Disease | Springfield, MA | $282,787 | $0 |
| Mace Rothenberg, Md, MD | Medical Oncology | Nashville, TN | $245,746 | $0 |
| Dr. Robin Beach, Fnp, FNP | Family | Bellaire, TX | $231,288 | $0 |
| Unknown Provider | — | — | $226,207 | $0 |
| Dr. Jihad Slim, Md, MD | Infectious Disease | Newark, NJ | $111,479 | $0 |
| Elizabeth Race, Md, MD | Infectious Disease | Dallas, TX | $96,009 | $0 |
| Brian Beesley, Do, DO | Family Medicine | Columbus, OH | $92,782 | $0 |
| Dr. Ricky Hsu, Md, MD | Internal Medicine | New York, NY | $77,493 | $0 |
| Dr. Jason Leider, M.d, M.D | Internal Medicine | Bronx, NY | $77,058 | $0 |
| Rohit Loomba, Md, MD | Internal Medicine | La Jolla, CA | $68,181 | $0 |
| Dr. Fred Sattler, M.d, M.D | Infectious Disease | Los Angeles, CA | $67,998 | $0 |
| Dr. Ronald Ellis, M.d., Ph.d, M.D., PH.D | Neurology | San Diego, CA | $62,500 | $0 |
| Dr. Daniel Lee, M.d, M.D | Infectious Disease | San Diego, CA | $49,463 | $0 |
| Dr. Claudio Tuda, M.d, M.D | Infectious Disease | Miami Beach, FL | $40,866 | $0 |
| Jeffrey Burack, M.d, M.D | Internal Medicine | Oakland, CA | $35,826 | $0 |
| Dr. Stephen Weinroth, Md, MD | Infectious Disease | Fairfax, VA | $34,155 | $0 |
| Princy Kumar | Infectious Disease | Washington, DC | $32,037 | $0 |
| Dr. Noah Lee, D.o, D.O | Family Medicine | Oakland Park, FL | $28,601 | $0 |
| Dr. Steven Grinspoon, Md, MD | Internal Medicine | Boston, MA | $28,298 | $0 |
| Sheetal Sharma, Md, MD | Internal Medicine | Fort Lauderdale, FL | $28,184 | $0 |
| Dr. Allison Eckard, Md, MD | Pediatrics | Charleston, SC | $25,887 | $0 |
| Edward Braun, Md, MD | Family Medicine | St Petersburg, FL | $25,852 | $0 |
| Bonnie Thomas, Md, MD | Internal Medicine | Chicago, IL | $24,906 | $0 |
| Brinda Emu, Md, MD | Internal Medicine | New Haven, CT | $23,764 | $0 |
| Michael Gottlieb, Md, MD | Specialist | Pasadena, CA | $21,179 | $0 |
Ad
Top Products
- EGRIFTA $3.1M
- TROGARZO $1.9M
Associated Products (3)
- EGRIFTA $3.1M
- TROGARZO $1.9M
- EGRIFTA SV $315,928
Payment Categories
- Food & Beverage $561,770
- Consulting $1.6M
- Travel & Lodging $338,906
- Research $3.3M
About Theratechnologies Inc.
Theratechnologies Inc. has made $8.0M in payments to 4,353 healthcare providers, recorded across 23,746 transactions in the CMS Open Payments database. In 2024, the company paid $486,804. The top product by payment volume is EGRIFTA ($3.1M).
Payments were distributed across 130 medical specialties. The top specialty by payment amount is Infectious Disease ($1.4M to 900 doctors).
Payment categories include: Food & Beverage ($561,770), Consulting ($1.6M), Research ($3.3M), Travel & Lodging ($338,906).
Theratechnologies Inc. is associated with 3 products in the CMS Open Payments database.